S1268
Clinical - Urology
ESTRO 2026
A retrospectiveanalysiswasconductedincludingpatients treatedwithcurativeintentforbladderpreservationbetw een 2018 and 2024. Patientsreceivedhypofractionatedradiotherapy o f 275 cGy per fraction in 20 sessions. Acute (<6 months) and late (>6 months) toxicitiesweregradedaccording to CTCAE v5.0. Survival curves wereestimatedusingthe Kaplan– Meier method. Results:
Conclusion: Adaptive SBRT enables safe treatment delivery for RCC abutting bowel – cases advised against under NCCN recommendations. Standard 5-mm PRV margin was insufficient to account for inter-fraction bowel motion. Adaptive planning preserved both target coverage and OAR safety, supporting its use for RCC adjacent bowel. References: 1. Rajoulh, C. et al. “Renal Function after Definitive Local Therapy for Primary Renal Cell Carcinoma: A Meta-Analysis.” International Journal of Radiation Oncology, Biology, Physics, Volume 120, Issue 2, S73 - S742. Siva, Shankar, et al. "Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial." The Lancet Oncology 25.3 (2024): 308-316. Keywords: Renal Cell Carcinoma, Adaptive SBRT Digital Poster 3503 Bladder preservation with concurrent chemoradiotherapy in muscle-invasive urothelial carcinoma: a two-institution experience Yuly C Ortiz 1 , Maria Rubio 1 , Ana Illescas 1 , Francisco J Rico 2 , Eva M Fernandez 3 , Jonathan Saavedra 1 1 Oncologia Radioterapica, Hospital Universitario Virgen Macarena, Sevilla, Spain. 2 Urologia, Hospital Universitario Nuestra Señora de Valme, Sevilla, Spain. 3 Oncologia Medica, Hospital Universitario Nuestra Señora de Valme, Sevilla, Spain
Thirty-sevenpatientswereincluded, with a median age of 78 years (IQR 73–82);
86% weremale. Clinicalstageswere T2 (54%), T3 (27%), and T4 (8%), all M0. Bladderpreservationwaselective in 24% and mandatory in 76% of cases.Radiotherapywascompleted in a median of 31 days (IQR 28– 37). Neoadjuvantchemotherapywasadministered in 43% and concurrentchemotherapy in 95% of patients, mainlywithgemcitabine (80%), cisplatin (17 %), orcarboplatin (3%).After a median follow-up of 30.1 months, 13 relapses (35%) wereobserved, mostlymetastatic (54 %). Post- relapsemanagementincludedsystemicchemotherapy ( 46%), salvagesurgery (23%), orpalliative/observationalc are (31%).At 2 years, overallsurvival (OS), progression- free survival (PFS), and cancer- specificsurvival (CSS) were 67%, 61%, and 73%, respectively.Median OS in themandatorypreservationgroupwas 18 months (95 % CI 9– 30), whileitwasnotreached in theelectivegroup.Acuteto xicitywas grade 1–2 in 69% and ≥ grade 3 in 8%, mainlycystitis and mild hematuria. Late toxicitywasdominatedbyurinaryincontinence (~30 %), with ≥ grade 3 in 3%, and no treatment- relateddeaths.
Purpose/Objective: To evaluateclinicaloutcomes, survival,
and toxicity of concurrentchemoradiotherapy (CRT) as a bladder-preservingstrategy in patientswithmuscle- invasiveurothelial carcinoma (MIBC). Material/Methods:
Made with FlippingBook - Share PDF online